Repatha Plateau & Non-Response Troubleshooting: A Clinical Guide to Evolocumab LDL Failure

What Counts as a Non-Response?

The Repatha label gives a timing rule rather than a response cutoff: it says to assess LDL-C when clinically appropriate, and that the LDL-lowering effect may be measured as early as 4 weeks after starting [1]. For the monthly regimen, the label specifies that LDL-C be measured just before the next dose [1].

The expected size of the effect depends on what it is compared with. In FOURIER, evolocumab lowered LDL-C by 59% versus placebo at 48 weeks, from a median baseline of 92 mg/dL to 30 mg/dL [2]. In LAPLACE-2, the LDL-C difference versus placebo was -71% with 140 mg every 2 weeks and -63% with 420 mg monthly in patients on background statins; versus ezetimibe 10 mg, the differences were -45% and -41% [1].

Check the Dose, Schedule and Storage First

A 420 mg monthly dose is three consecutive 140 mg injections within 30 minutes [1]. A single injection delivers 140 mg, not the monthly 420 mg dose [1]. The label describes different missed-dose schedules: a dose given within 7 days of being missed is followed by the original schedule; when a dose is more than 7 days late, the every-2-week regimen waits for the next scheduled dose, while the monthly regimen uses the late dose to start a new schedule [1]. The label directs injection into the abdomen, thigh or upper arm and rotation of sites [1].

Storage is part of the same check. The label says to keep Repatha refrigerated at 2 to 8 C in the carton, not to freeze or shake it, and that it may be kept at room temperature (20 to 25 C) in the carton for up to 30 days [1]. The label says to allow the pen or syringe to warm for 30 minutes before injection [1]. Some presentations contain dry natural rubber in the needle cover, and latex-free presentations exist [1].

HoFH and the 12-Week Dose Decision

For adults and children 10 years and older with HoFH, the label starts at 420 mg once monthly and allows an increase to 420 mg every 2 weeks if a clinically meaningful response is not achieved by 12 weeks [1]. Patients on lipid apheresis may start at 420 mg every 2 weeks, with the dose given after the apheresis session [1].

TESLA Part B randomized 50 patients with HoFH (aged 12 years or older, not on apheresis) 2:1 to evolocumab 420 mg every 4 weeks or placebo for 12 weeks. Forty-nine received study drug (33 evolocumab, 16 placebo) and completed the study [3]. Evolocumab reduced ultracentrifugation LDL-C by 30.9% versus placebo at 12 weeks (95% CI -43.9 to -18.0; p < 0.0001) [3].

What the Label Says About Statins and Other Drugs

The Repatha label has no drug interactions section [1]. It reports about 20% lower evolocumab Cmax and AUC in adults on a high-intensity statin and calls that difference not clinically meaningful [1]. No dose adjustment is needed for renal impairment or mild to moderate hepatic impairment [1]. In severe renal impairment or hemodialysis, exposure was lower but PCSK9 reduction was similar [1]. Age, sex, race and creatinine clearance did not affect evolocumab pharmacokinetics [1].

Does Response Fade Over Time?

In the label's FOURIER data, the LDL-C difference versus placebo was -63% at week 12 and -57% at week 72 [1]. The paper reported a 59% reduction at 48 weeks [2].